---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046015"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:20.089674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Roivant Q2 loss $236.8M; Dermavant deal closed; cash $5.4B; brepocitinib NIU data

## Summary
- Q2 loss from continuing ops $236.8M ($0.25 EPS); R&D $143.1M; G&A $202.9M up $114.3M YoY on retention awards.
- Dermavant transaction closed Oct 28: Roivant received $184M cash; Organon assumed $336M debt; $75M milestone pending VTAMA FDA approval for atopic dermatitis.
- Consolidated cash, cash equivalents and marketable securities ~$5.4B at Sep 30, 2024.
- Share repurchases $106M in Q2; cumulative $754M (incl. Sumitomo stake buyback).
- Pipeline: brepocitinib Phase 2 NIU 52-wk data shows sustained efficacy; batoclimab GD 76% response; mosliciguat PVR reduction ~38%.

## SEC filing metadata
- accession: 0001140361-24-046015
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/0001140361-24-046015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046015
- JSON: https://secwatch.observer/filing/0001140361-24-046015.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.